More on Health Care

Sep 28, 2016

EpiPen investigation shows need for greater pricing transparency, other reforms

Congressman Lynch wrote an op-ed for The Hill highlighting the need for greater pricing transparency and other reforms in the wake of Mylan's EpiPen price hikes.

Sep 26, 2016

Mylan’s EpiPen Pretax Profits 60% Higher Than Number Told to Congress

The $100 profit figure, or $50 per pen, was greeted with incredulity by committee members. Rep. Stephen Lynch said “the numbers don’t work, based on the documents you’ve given us.”

Sep 25, 2016

On The Record

Near the 4:50 mark, WCVB On The Record highlights Congressman Lynch's questioning of Mylan CEO Heather Bresch at the recent Oversight hearing on EpiPens.

Sep 23, 2016

Congressman Stephen Lynch on EpiPen

Congressman Lynch joins Kim Carrigan and VB on the WRKO/Boston.com Morning Show to discuss the recent oversight hearing on EpiPen price increases.

Pages